Integrative Functional & Lifestyle Medicine + LDN & More to help us survive, overcome, and thrive beyond our medical challenges. MCAS, CFS, ME, Chronic Pain, Fibromyalgia, Autoimmune and More

Latest

The LDN–Cell Danger Response Convergence Hypothesis: Could Low-Dose Naltrexone Indirectly Modulate Purinergic Signaling in Chronic Subclinical Inflammation and HPG-Axis Suppression? — A Hypothesis

The LDN–Cell Danger Response Convergence Hypothesis: Could Low-Dose Naltrexone Indirectly Modulate Purinergic Signaling in Chronic Subclinical Inflammation and HPG-Axis Suppression? — A Hypothesis

Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician What this article is — and is not. This is a hypothesis. It proposes a biologically plausible, testable model in which low-dose naltrexone (LDN) might indirectly influence purinergic “cell danger” signaling and, in turn, inflammation-

By Yoon Hang Kim MD

Pseudomonas aeruginosa in the Gut: When It Matters, How to Treat It, and an Honest Look at Botanicals and Probiotics

Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician ⚕ Medical Disclaimer This article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The strategies discussed should be implemented only under the guidance of a qualified healthcare provider.

By Yoon Hang Kim MD

Low-Dose Naltrexone and mTOR Inhibitor Therapy in Pediatric NPRL3-Related Focal Epilepsy with Neuroinflammation: A Clinical Review and Evidence-Based Dosing Framework

Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Published: July 2026  |  www.directintegrativecare.com Medical Disclaimer: This article is intended for educational and clinical reference purposes only. It does not establish a physician–client relationship. All therapeutic decisions must be made by the

By Yoon Hang Kim MD